Physiological responses to increased dietary cholesterol: The case of the egg man by Gumucio, Jorge J. et al.
HEPATOLOGY Ekewhere 
JORGE J. GUMUCIO, EDITOR 
Department of Internal Medicine 
Division of Gastroenterology ( 11 1D) 
VA Medical CenterKJniversity of Michigan 
Ann Arbor, Michigan 48105 
Elsewhere Reviews 
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INCREASED DIETARY CHOLESTEROL THE CASE 
OF THE EGG MAN 
Kern F Jr. Normal plasma cholesterol in an 88-year-old 
man who eats 25 eggs a day. N Engl J Med 1991;324: 
896-899. 
EDITOR’S SUMMARY 
An 88-yr-old man carrying the tentative diagnosis of 
Alzheimer’s disease had a documented history of in- 
gesting 20 to 30 eggs/day for approximately 15 yr. His 
psychiatrist characterized his eating habits as a com- 
pulsive disorder: “Eating these eggs ruins my life, but 
I can’t help it.” He is in excellent health. His weight is 
constant at 82 to 86 kg (height 1.87 m). Apparently, he 
had a mild episode of angina. Otherwise, no significant 
history of stroke, heart disease or gallbladder disease 
was seen. His serum cholesterol levels have ranged 
between 150 and 200 mg/dl. 
COMMENTS 
Individuals differ widely in their responses to dietary 
cholesterol. A rigorous cholesterol-lowering diet often 
can reduce serum cholesterol in hyperlipidemic patients 
by 40 to 50 mg/dl(l), and the feeding of high-cholesterol 
diets on a metabolic ward can increase mean serum 
cholesterol. However, many individuals exhibit little or 
no change in serum cholesterol despite large changes in 
diet. A broad division may be made between those 
individuals who, in response to changes in dietary 
cholesterol, display parallel changes in serum lipids 
(noncompensators) and those who do not (compensa- 
tors). A recent study by McNamara and colleagues (2) 
found that of 75 male volunteers, 52 (69%) were 
compensators, which was defined as a change of less 
than 5% in plasma cholesterol after a dietary cholesterol 
challenge. The metabolic and genetic factors that de- 
termine our responses to dietary cholesterol are not well 
understood. 
Kern in this unusual case has identified some novel 
mechanisms by which certain human beings may com- 
pensate for massive amounts of dietary cholesterol. The 
patient reported was an 88-yr-old man with a compulsive 
craving for eggs, which led him to consume 20 to 30 eggs 
(approximately 5,000 mg of cholesterol) each day for a 
period of at least 15 yr. Despite this practice, the patient 
(hereafter called “the egg man”) had little evidence of 
atherosclerotic disease, and serum cholesterol measure- 
ments were consistently less than 200 mg/dl. Using 
established methods, Kern measured cholesterol ab- 
sorption, cholesterol synthesis and bile acid kinetics and 
compared the results in this patient to findings in 11 
normal individuals (controls) maintained for 2 to 3 wk 
on low-cholesterol (219 mg/day) or high-cholesterol 
(1,156 mg/day) diets. 
The metabolism of the egg man appears to have 
adapted in three ways to his massive cholesterol load. 
First, synthesis of cholesterol was 16% lower than in 
control subjects fed a low-cholesterol diet, a degree of 
suppression similar to that noted when control subjects 
consumed a high-cholesterol diet. Second, although total 
cholesterol absorption was high, fractional absorption of 
dietary cholesterol was only 18%; this contrasted with 
mean cholesterol absorption of 55% and 46% for control 
subjects, respectively, on low-cholesterol or high- 
cholesterol diets. Third, the egg man’s rate of bile acid 
synthesis (the principal pathway of cholesterol degra- 
dation) was increased to levels twice those of controls on 
low-cholesterol diets; in contrast, the feeding of high- 
cholesterol diets to control subjects produced no increase 
in bile acid synthesis. The bile acid pool size of the egg 
man also was twice a control’s, indicating that his 
increased bile acid synthesis probably was not attrib- 
utable to bile acid malabsorption. 
The case of the egg man is important because it 
indicates that intestinal cholesterol absorption and 
hepatic bile acid synthesis in some human beings may be 
regulated over a wide range to compensate fully for 
changes in dietary cholesterol. Two important caveats 
are in order. Without restudying the same patient after 
a period of abstinence from cholesterol, we cannot be 
certain that the observed abnormalities are truly 
adaptive to dietary cholesterol, as opposed to unrelated 
genotypic or phenotypic variation. And even if the 
observed abnormalities are truly adaptive, we cannot 
estimate from this one case how frequently others would 
respond in the same way to such a massive cholesterol 
load. Nonetheless, it seems unlikely that the coexistence 
of three unusual findings (massive dietary cholesterol 
intake, low fractional cholesterol absorption and high 
bile acid synthesis) can be attributed to coincidence. 
Absorption of cholesterol from the intestine is thought 
to be a passive process requiring solubilization with bile 
salts in mixed micelles and diffusion across an unstirred 
layer to the surface of the mucosal cell (3). The physical 
chemistry of this process is complex, and the specific 
rate-determining events are poorly understood. Animal 
studies suggest that the capacity for cholesterol uptake 
is limited (41, and it is possible that the low fractional 
absorption of cholesterol in Kern’s patient results 
simply from saturation of a passive uptake system. 
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Evidence suggests, however, that dietary cholesterol 
absorption may not be a completely passive phe- 
nomenon. Several authors have suggested the existence 
of a brush-border transport protein that may be involved 
in the uptake of cholesterol from the intestinal lumen (5, 
6). Kern speculates that this putative transfer protein 
may be down-regulated in the egg man, leading to the 
unusually low fractional cholesterol absorption. One 
might further speculate that inhibitors directed against 
a cholesterol transfer protein would be useful hypocho- 
lesterolemic agents. Clearly, this is an area that requires 
further investigation. 
The most intriguing finding in the egg man was his 
marked increase in bile acid synthesis - described by 
Kern as “greater than in any of the 200 subjects we have 
studied during the past 13 years.” Bile acid synthesis is 
a major pathway of cholesterol elimination, and a 
mechanism linking the rate of bile acid synthesis to the 
cholesterol supply could contribute to cholesterol ho- 
meostasis. The role of cholesterol in regulation of 
human bile acid synthesis is controversial (7). 
In the rat, activity of cholesterol 7a-hydroxylase, the 
principal rate-determining enzyme in the bile acid 
biosynthetic pathway, increases in response to choles- 
terol feeding (8). Conversely, inhibition of cholesterol 
synthesis by inhibitors acting at early or late steps in the 
cholesterol biosynthetic pathway leads to rapid and 
reversible down-regulation of bile acid synthesis and 
cholesterol 7a-hydroxylase activity (9, 10). Recent data 
indicate that these regulatory changes occur principally 
at a pretranslational level through effects on tran- 
scription of the cholesterol 7a-hydroxylase gene and 
possibly also on turnover of cholesterol 7a-hydroxylase 
messenger RNA (Unpublished observations). The mech- 
anism appears independent of the negative feedback 
inhibition of cholesterol 7a-hydroxylase by bile salts, 
which is thought to be mediated at a transcriptional level 
(11). In contrast to the rat, studies in human beings, 
including Kern’s control group in this study, generally 
have shown little or no increase in bile acid synthesis in 
response to increased dietary cholesterol, although a 
single study by Lin and Conner (12) suggested that 
cholesterol feeding increased excretion of acidic sterols 
(bile salts) in feces. Recently, however, Mitchell and 
colleagues (13) found that the administration of lova- 
statin to human subjects leads to a 50% drop in the rate 
of bile acid synthesis, consistent with previous findings 
in the rat. 
How can we best put these data into perspective? 
Failure to detect up-regulation of bile acid synthesis in 
previous cholesterol feeding studies may indicate that 
this mechanism of adaptation in humans is operative 
only in the face of extreme changes in hepatic choles- 
terol, such as the extremely high cholesterol diet of the 
egg man or the acute inhibition of cholesterol synthesis 
by lovastatin. Alternatively, the capacity to regulate bile 
acid synthesis in response to changes in the supply of 
cholesterol may be a genetic variant and may account for 
the ability of some individuals to maintain normal 
serum cholesterol in the face of a high cholesterol diet. 
Within the past 2 yr the gene for rat cholesterol 
7a-hydroxylase has been cloned (14, 15). Intensive 
efforts currently are under way to dissect the 5’ 
regulatory region of this gene to explain the molecular 
mechanisms of the regulation of this important enzyme. 
In the future it may be possible to identify structural 
variations in the cholesterol 7a-hydroxylase gene that 
are responsible for interindividual and interspecies 
differences in regulation of bile acid synthesis by 
cholesterol, as previously has been the case for the 
low-density lipoprotein receptor and for apolipoprotein 
E (16, 17, 18). 
Because of its role in atherosclerotic and coronary 
artery disease, serum cholesterol has been the subject of 
great attention. It must be kept in mind, however, that 
this is but one parameter of overall cholesterol homeo- 
stasis. Cholesterol metabolism is a complex process 
involving many branching metabolic pathways. These 
pathways are in turn regulated by a number of different 
molecules (apoproteins, receptors and enzymes) that are 
under both genetic and metabolic control. Given the 
complexity of the process, it is not surprising that 
individual responses to dietary cholesterol are so het- 
erogeneous. Future efforts will need to address the 
genetic and physiological basis for these varied re- 
sponses to more accurately identify those patients who 
would benefit from particular forms of dietary and 
pharmacological therapies. For now, we should keep in 
mind that some people, like the egg man, appear well 
adapted to the high cholesterol diet of Western society. 
To the extent that such individuals can be identified, it 
would be wrong to use our authority as counseling 
physicians to deny them the simple gustatory pleasures 
and nutritional benefits of the omelette, the custard and 
the souffl6. 
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Richmond, VA 23298 
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EXCELLENT PROGNOSIS IN WILSONIAN 
CmONIC ACTIVE HEPATITIS: NEW DATA OR AN 
ARTICLE OF FAITH? 
Schilsky ML, Scheinberg IH, Sternlieb I. Prognosis of 
Wilsonian chronic active hepatitis. Gastroenterology 
1991;100:762-767. 
ABSTRACT 
Twenty of 320 patients with Wilson’s disease initially 
presented with chemical and laboratory features of 
chronic active hepatitis, confirmed histologically 
in 17. When h t  seen, Cirrhosis was present in all 20 
and was complicated by ascites and/or jaundice in 11. 
Within 1 week to 8 years of the onset of overt liver 
disease the diagnosis of Wilson’s disease was estab- 
lished, and treatment with D-peniciuamine was 
promptly initiated in 19 patients. One man refused 
treatment and died 4 months later. Treated patients 
received D-penicillamine or trientine for a total of 264 
patient-years (median, 14 patient-years). Abnormal 
water retention, for which salt restriction and di- 
uretics were added to penicillamine or trientine, dis- 
appeared in all but 1 of the patients so affected. 
Symptomatic improvement and virtually normal 
levels of serum albumin, bilirubin, aspartate ami- 
notransferase, and alanine aminotransferase followed 
within 1 year in the mqjority of subjects. One woman 
died after 9 months of treatment. Two patients, who 
became noncompliant with the therapeutic regimen 
after 9 and 17 years of successful pharmacological 
treatment, required liver transplants. These results 
indicate that the prognosis of specifically treated 
Wilsonian chronic active hepatitis is very good in spite 
of the presence of cirrhosis. 
COMMENTS 
Cirrhosis was part of the original description of 
Wilson’s disease, and death from liver failure was 
probably recognized as early as 1916 (1). With theadvent 
of effective treatment with penicillamine, Wilsonian 
CAH has become the hepatological diagnosis that must 
not be missed! Just how good the prognosis can be is 
emphasized in this report. Although one patient died at 
9 mo and 2 who became noncompliant with penicil- 
lamine treatment required liver transplantation, all 16 
treated patients have done well for between 4 and 25 yr 
despite the presence of cirrhosis at the time of diagnosis. 
Twenty (6.25%) of the 320 patients in the authors’ 
series of Wilson’s disease patients met the authors’ 
criteria for histological and/or clinical features of CAH. 
In a previous study from the same group, it was reported 
that 42% of 151 symptomatic cases of Wilson’s disease 
(which are presumably included in this study) had an 
initial hepatic manifestation (2). It seems clear, 
therefore, that the patients reported in this article 
represent a small subset of hepatic Wilson’s disease and 
that the authors are drawing a clear distinction between 
Wilson’s disease appearing as CAH and other forms of 
hepatic Wilson’s disease, including fatty change, inactive 
cirrhosis and fulminant hepatitis. It would have been 
interesting to know how many of their total series fell 
into these other categories. Do the authors consider 
Wibonian CAH to be part of a progression from an acute 
hepatitis-like injury to the characteristic inactive cir- 
rhosis, or is it a distinct pathological entity? Likewise, is 
the feared fulminant presentation of Wilson’s disease a 
distinct pathological entity or part of the spectrum of 
CAH? These questions are important because the 
reported excellent outcome of this particular type of 
Wilsonian chronic liver disease must, to some degree, 
depend on the extent to which it can be separated and 
distinguished from other varieties and from CAH of 
non-Wilsonian cause. For example, the experience of the 
Royal Free group (3), which had a similar series of 
patients with Wilson’s disease appearing as CAH, 
was much less encouraging. They noted that “de- 
spite D-penicillamine therapy. . .4 patients died within 
three weeks of diagnosis from fulminant hepatic 
failure. . . (and) a further 5 patients died within 2 
years. . . .” 
The diagnosis of Wilson’s disease in the patients 
described by Schilsky, Scheinberg and Sternlieb, as 
would be expected in a paper from this group, appears to 
be beyond question. Nonetheless, we are told that 
several other causes of CAH, “including hepatitis type B, 
